PPD Inc. (PPD)
Company Description
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide.
The company operates through Clinical Development Services and Laboratory Services segments.
It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services.
The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services.
It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants.
The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Country | United States |
| IPO Date | Feb 6, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 30,000 |
| CEO | David S. Simmons |
Contact Details
Address: 929 North Front Street Wilmington, NORTH CAROLINA United States | |
| Website | http://www.ppd.com |
Stock Details
| Ticker Symbol | PPD |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001793294 |
| CUSIP Number | 69355F102 |
| ISIN Number | US69355F1021 |
| Employer ID | 45-3806427 |
| SIC Code | 8731 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2024 | 4 | Filing |
| Feb 08, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 02, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 20, 2021 | 15-12B | Filing |
| Dec 09, 2021 | 4 | Filing |
| Dec 09, 2021 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 08, 2021 | 4 | Filing |
| Dec 08, 2021 | 4 | Filing |
| Dec 08, 2021 | 4 | Filing |
| Dec 08, 2021 | 4 | Filing |